Lantern Pharma Book Value Per Share vs. Debt To Equity
| LTRN Stock | USD 3.21 0.10 3.22% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 3.77297149 | Current Value 2.5 | Quarterly Volatility 2.24913471 |
For Lantern Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lantern Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lantern Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lantern Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lantern Pharma over time as well as its relative position and ranking within its peers.
Lantern |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lantern Pharma Debt To Equity vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lantern Pharma's current stock value. Our valuation model uses many indicators to compare Lantern Pharma value to that of its competitors to determine the firm's financial worth. Lantern Pharma is rated fifth overall in book value per share category among its peers. It also is rated fifth overall in debt to equity category among its peers . The ratio of Book Value Per Share to Debt To Equity for Lantern Pharma is about 1,908 . At this time, Lantern Pharma's Book Value Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lantern Pharma's earnings, one of the primary drivers of an investment's value.Lantern Debt To Equity vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Lantern Pharma |
| = | 3.82 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Lantern Pharma |
| = | 0 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Lantern Debt To Equity Comparison
Lantern Pharma is currently under evaluation in debt to equity category among its peers.
Lantern Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lantern Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lantern Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Lantern Pharma's change in net profit over the period of time. It can combine multiple indicators of Lantern Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -107.5 K | -112.8 K | |
| Operating Income | -17.9 M | -17 M | |
| Net Loss | -15.2 M | -14.4 M | |
| Income Before Tax | -16 M | -15.2 M | |
| Net Loss | -12.8 M | -12.2 M | |
| Net Loss | -16 M | -15.2 M | |
| Income Tax Expense | (3.00) | (3.15) | |
| Total Other Income Expense Net | 1.9 M | 2 M | |
| Net Interest Income | 572.7 K | 601.3 K | |
| Interest Income | 572.7 K | 601.3 K | |
| Change To Netincome | 2 M | 2.1 M | |
| Net Loss | (1.47) | (1.55) | |
| Income Quality | 0.90 | 0.70 | |
| Net Income Per E B T | 1.14 | 1.09 |
Lantern Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lantern Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lantern Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lantern Pharma's important profitability drivers and their relationship over time.
Use Lantern Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lantern Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lantern Pharma will appreciate offsetting losses from the drop in the long position's value.Lantern Pharma Pair Trading
Lantern Pharma Pair Trading Analysis
The ability to find closely correlated positions to Lantern Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lantern Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lantern Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lantern Pharma to buy it.
The correlation of Lantern Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lantern Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lantern Pharma position
In addition to having Lantern Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Absolute Returns ETFs Thematic Idea Now
Absolute Returns ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Absolute Returns ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Absolute Returns ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
To fully project Lantern Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lantern Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lantern Pharma's income statement, its balance sheet, and the statement of cash flows.